Introduction:Basic information about CAS 312-93-6|Dexamethasone Phosphate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Dexamethasone Phosphate |
|---|
| CAS Number | 312-93-6 | Molecular Weight | 472.44100 |
|---|
| Density | 1.45g/cm3 | Boiling Point | 669.6ºC at 760mmHg |
|---|
| Molecular Formula | C22H30FO8P | Melting Point | 154-157°C (lit.) |
|---|
| MSDS | / | Flash Point | 358.7ºC |
|---|
Names
| Name | dexamethasone phosphate |
|---|
| Synonym | More Synonyms |
|---|
Dexamethasone Phosphate BiologicalActivity
| Description | Dexamethasone phosphate (Dexamethasone 21-phosphate) is a biologically inactive compound which undergoes dephosphorylation by intra-erythrocyte enzymes. The active metabolite, dexamethasone, is then released into the circulation by simple passive diffusion through cell membranes. Dexamethasone phosphate-encapsulated erythrocyte has the potential for steroid-dependent ulcerative colitis research[1]. |
|---|
| Related Catalog | Research Areas >>Inflammation/ImmunologySignaling Pathways >>GPCR/G Protein >>Glucocorticoid Receptor |
|---|
| References | [1]. Fabrizio Bossa, et al. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis. 2013 Aug;19(9):1872-9. |
|---|
Chemical & Physical Properties
| Density | 1.45g/cm3 |
|---|
| Boiling Point | 669.6ºC at 760mmHg |
|---|
| Melting Point | 154-157°C (lit.) |
|---|
| Molecular Formula | C22H30FO8P |
|---|
| Molecular Weight | 472.44100 |
|---|
| Flash Point | 358.7ºC |
|---|
| Exact Mass | 472.16600 |
|---|
| PSA | 151.17000 |
|---|
| LogP | 2.01270 |
|---|
| Index of Refraction | 1.594 |
|---|
| InChIKey | VQODGRNSFPNSQE-CXSFZGCWSA-N |
|---|
| SMILES | CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)(O)O |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- TU4055000
- CHEMICAL NAME :
- Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-alpha-methyl-, 21-(dihydrogen phosphate)
- CAS REGISTRY NUMBER :
- 312-93-6
- LAST UPDATED :
- 199706
- DATA ITEMS CITED :
- 14
- MOLECULAR FORMULA :
- C22-H30-F-O8-P
- MOLECULAR WEIGHT :
- 472.49
- WISWESSER LINE NOTATION :
- L E5 B666 OV AHTTT&J A1 BF CQ E1 FV1OPQQO FQ G1
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- LD - Lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >1 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 36 mg/kg/90D-I
- TOXIC EFFECTS :
- Endocrine - changes in thymus weight Immunological Including Allergic - decrease in cellular immune response Immunological Including Allergic - decrease in humoral immune response
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 600 ug/kg
- SEX/DURATION :
- female 21-22 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - endocrine system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 200 ug/kg
- SEX/DURATION :
- female 19-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 400 ug/kg
- SEX/DURATION :
- female 19-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - hepatobiliary system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 30 mg/kg
- SEX/DURATION :
- female 8-13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 2 mg/kg
- SEX/DURATION :
- female 1 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - other measures of fertility
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 600 ug/kg
- SEX/DURATION :
- female 17-19 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - respiratory system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 600 ug/kg
- SEX/DURATION :
- female 17-19 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- DOSE :
- 1 mg/kg
- SEX/DURATION :
- female 11-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- DOSE :
- 1 mg/kg
- SEX/DURATION :
- female 14-17 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- DOSE :
- 1 mg/kg
- SEX/DURATION :
- female 22-25 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
MUTATION DATA - TEST SYSTEM :
- Rodent - rat
- DOSE/DURATION :
- 3 mg/kg
- REFERENCE :
- JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939- Volume(issue)/page/year: 62,527,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3850 No. of Facilities: 130 (estimated) No. of Industries: 3 No. of Occupations: 10 No. of Employees: 5388 (estimated) No. of Female Employees: 2968 (estimated)
|
Safety Information
| Hazard Codes | Xn |
|---|
| Risk Phrases | 62 |
|---|
| HS Code | 2937290090 |
|---|
Customs
Synonyms
| Hexadrol phosphate |
| dexamethasone-21-phosphate |
| Dexamethasone 21-orthophosphate |
| Betnelan phosphate |
| Dexamethasone-21-dihydrogen-phosphate |
| Wymesone |
| Neodecadron |
| Oradexon phosphate |
| Dexamethasone phosphate |
| [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate |